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Abstract Congenital myasthenic syndromes are a clini-
cally and genetically heterogeneous group of hereditary
disorders affecting neuromuscular transmission. We have
identified mutations within the acetylcholine receptor
(AChR) e-subunit gene underlying congenital myasthenic
syndromes in nine patients (seven kinships) of Dutch ori-
gin. Previously reported mutations e1369delG and eR311Q
were found to be common; e1369delG was present on at
least one allele in seven of the nine patients, and eR311Q in
six. Phenotypes ranged from relatively mild ptosis and
external ophthalmoplegia to generalized myasthenia. The
common occurrence of eR311Q and e1369delG suggests a
possible founder for each of these mutations originating in
North Western Europe, possibly in Holland. Knowledge of
the ethnic or geographic origin within Europe of AChR
deficiency patients can help in targeting genetic screening
and it may be possible to provide a rapid genetic diagnosis
for patients of Dutch origin by screening first for eR311Q
and e1369delG.
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a-BuTx 125I-a-Bungarotoxin
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CHRNE AChR e-subunit gene
CMS Congenital myasthenic syndrome
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Introduction
The congenital myasthenic syndromes (CMSs) are a group of
hereditary disorders affecting neuromuscular transmission
[1–3]. The disorders are clinically and genetically heteroge-
neous [4]. Patients frequently present at birth or within the first
two years of life. Most present with ocular, bulbar or respi-
ratory muscle symptoms, worsened by crying or activity. The
majority of CMSs primarily affect postsynaptic function, and
are caused by mutations in subunits of the acetylcholine
receptor (AChR), in the AChR-clustering protein rapsyn, or in
DOK7. The AChR mutations may alter kinetic properties
(slow- and fast-channel syndromes), decrease expression of
the AChR pentamer (AChR deficiency) [5] or alter kinetic
properties and decrease expression. Many mutations that
decrease AChR expression reside in the AChR e-subunit gene
[6], with the resulting AChR deficiency phenotype inherited
as an autosomal–recessive trait [3, 5, 7].
CMSs are relatively rare disorders that may be difficult
to diagnose in infants and early childhood. Many of the
AChR e-subunit gene mutations are restricted to a single or
only a few kinships. Consequently, genetic screening for
AChR deficiency frequently requires thorough analysis of
the whole of the e-subunit gene. Here we present the cases
of nine patients (seven kinships) for whom the diagnosis of
congenital myasthenia has recently been confirmed by
genetic analysis. We find a common occurrence of muta-
tions eR311Q and e1369delG in AChR deficiency patients
of Dutch origin.
Patients and methods
We identified nine CMS patients in the Netherlands (Table 1).
All patients were of Dutch origin and Caucasian. Patients 3–8
have been reported before by the late Dr. Oosterhuis before
mutation analysis was performed [8]. Antibodies to the AChR
were absent in all cases. Patients generally presented with
ptosis and ophthalmoparesis from infancy or early childhood.
Some of them had swallowing difficulties or proximal muscle
weakness later on. Neostigmine had a moderate effect in most
patients. Some patients remained stable throughout life,
whereas others slowly declined in muscle strength.
Patient 1, a 14-year-old boy with non-consanguine
parents, presented at the age of two and a half years with
ptosis and ophthalmoparesis. The ptosis had been present
from birth. He remained stable until the age of 10, when he
presented with a rapid progressive weakness involving his
arms, legs and bulbar muscles, following a flu-like disease.
These symptoms resolved spontaneously after a few days.
He improved after administration of neostigmine. Repeti-
tive nerve stimulation showed no decrement of compound
muscle action potentials (CMAPs), nor repetitive CMAPs.
Patient 2 is the younger brother of patient 1, who
according to the parents had symptoms of ophthalmopa-
resis and ptosis at the age of two years. No muscle weak-
ness of arms or legs was noted. His parents did not request
further investigations to be made. His current age is
9 years, and he has apparently been stable so far.
Patient 3 had drooping eyelids from early infancy, and
was never able to run. At the age of 23 she had ptosis at
both eyes, a nearly complete ophthalmoplegia, mild facial
weakness and mild weakness of the limbs. She improved
after treatment with neostigmine. During the following
years her symptoms remained unchanged.
Patient 4 is a 24-year-old man who has had swallowing
difficulties from birth. At the time of the biopsy (when he
was 5 years old) he had drooping eyelids and difficulties
Table 1 Patients with congenital myasthenic syndrome in the Netherlands and e1369delG and/or eR311Q mutations
Patient
number
Age at onset
(years)
Sex Age at diagnosis
(years)
First
symptoms
Actual age
(years)
Actual
symptoms
Mutations found in AChR
e-subunit gene
1 Birth Male 2 P 14 P, O, B, L e1369delG eR311 eR311Q
2 2 Male 2 P, O 9 P, O e1369delG eR311Q
3 Birth Female 7 P 48 P, O, L e1369delG e1369delG
4 Birth Male 4 B 24 P, O, L e1369delG e 509insA
5 1 Female 54 P 74 P, O, L e1369delG eR311Q
6 3 Male 38 P 80 P, O. L e1369delG eR311Q
7 Birth Male 8 P, B 38 P, O, L eR311Q eR311Q
8 Infancy Male 18 B 32 P, O, L e1369delG e Y15H
9 Infancy Female 50 P 53 P, O, L e R64X eR311Q
P ptosis, O external ophthalmoplegia, B bulbar symptoms, L limb weakness
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with swallowing. Running with other boys was difficult.
Neostigmine, and later mytelase was given from 4 years
onwards which provided some improvement. On his last
neurologic examination in 2004 he still used neostigmine,
with a moderate effect, and his symptoms remained
unchanged. Repetitive nerve stimulation showed a decre-
ment of CMAPs.
Patient 5, a 74-year-old woman with unrelated parents,
had drooping eyelids from the age of 1 year. Mild gener-
alised weakness especially in arms and hands, impeded her
with children’s games. At 15 years myasthenia gravis was
diagnosed and pyridostigmine was found to have a bene-
ficial effect. Her condition gradually worsened and when
she was 51 years old she had diplopia, chewing difficulties
and outdoors she became wheelchair dependent. At the
time of the biopsy (when she was 58 years old) the muscle
bulk was very small, with weakness of the deltoid, arm and
leg muscles. The 5th CMAP (3 Hz) of the abductor pollicis
brevis showed a 10% decrement. In the following 17 years
the generalised weakness progressed further.
Patient 6, an 80-year-old man (brother of patient 5) had
drooping eyelids from early childhood. He had dyspnea
after climbing the stairs while he was at primary school.
There were no diurnal fluctuations of symptoms, but there
were bad days, especially when it was cold. He responded
well to treatment with pyridostigmine, which was initiated
only when he was 60 years old. At the time of the biopsy
(when he was 64 years old) the muscle bulk was small but
without obvious atrophy. He could not rise from his chair
without the help from his arms. The 5th CMAP (3 Hz) of
the abductor digiti minimi muscle showed a 10% decre-
ment. In the following 20 years the generalised weakness
progressed further.
Patient 7 is a 38-year-old man who had drooping
eyelids and weak facial muscles since birth. At the time
of the biopsy (when he was 19 years old) he had double
vision in the morning, ptosis, and diffuse weakness of the
limbs.
Patient 8 is a 32-year-old man who experienced feeding
difficulties due to a weak suck after birth. At the end of his
first year he developed drooping eyelids. At the age of
4 years he developed limb weakness. He was never able to
stand up without aid of his hand, and could not run. At the
age of 18 years he had generalized proximal weakness of
his limbs, ptosis, and intermittent diplopia.
Patient 9 is a 53-year-old woman with symmetrical
ptosis without double vision since infancy and walking
difficulties in childhood. She had to drink with her meals to
make swallowing easier. At the age of 50 years she had
severe ptosis with very restricted eye movements and
sometimes double vision. She is quickly tired in her limbs
and is unable to rise from a chair without support. Her
fatigue disappeared completely with pyridostigmine.
Genetic analysis
Genomic DNA from patient and control samples was isolated
from peripheral blood using the NucleonTM II DNA extraction
kit (Nucleon Biosciences). Coding exons and regions of the
promoter of the AChR e-subunit gene were amplified using the
polymerase chain reaction (PCR) and amplicons screened for
mutations by direct DNA sequencing. DNA changes were
confirmed by restriction endonuclease digestion and size
fractionation by agarose gel electrophoresis. The detected
mutations were not observed in restriction digests of 100
control samples. Functional effects of the missense mutations
were confirmed by studies of the mutant AChR expressed in
HEK 293 cells [9].
Oligonucleotides 5
0
-CAAACAGGATATCCAAGGCC
ACTAC-30 and 50-CTTCCCCCAAACTCCAGGGAATG
GAG-30 were used in PCR reactions to amplify a section of
the CHRNE 30 untranslated region that harbours a cluster
of SNPs (http://www.ncbi.nlm.nih.gov/SNP/).
Haplotypes were determined by DNA sequence analysis
of CMS patients and relatives. Gene frequency for the G or
C nucleotide at SNP rs9914357 was determined by DNA
sequencing of 100 control chromosomes. SNPs with minor
allele frequency [25% (CEPH) were selected.
Data from screening over 100 suspected CMS cases of
Northern European origin that did not have CHRNE mutations
gave similar allele frequencies to the CEPH population.
Results
Mutation analysis
Screening of DNA from patients 1–9 identified mutations in
the AChR e-subunit gene (CHRNE). Five different mutations
were identified: eY15H, eR64X, e509insA, eR311Q,
e1369delG. Previous functional studies of these mutations
have shown that eR311Q results in severely reduced expres-
sion of adult-type AChR with near normal ion-channel
properties, whereas e1369delG is a null mutation [9]. Four
patients (two were siblings) are compound heterozygous for
eR311Q/e1369delG, one is homozygous for eR311Q, one
homozygous for e1369delG, two harbour a null allele in
combination with e1369delG, and one a null allele in combi-
nation with eR311Q (Table 1; Fig. 1). Strikingly, all patients
harboured at least one copy of either eR311Q or e1369delG.
Haplotype analysis
To investigate the possibility that eR311Q and e1369delG
may be derived from original founder mutations we ana-
lysed a cluster of four single nucleotide polymorphisms
(SNPs), rs1053754, rs8834, rs7774, rs9914357, that are
J Neurol (2009) 256:1719–1723 1721
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located within the 30 untranslated region of CHRNE.
Haplotypes for patients and family members for the four
SNPs were determined (Table 2; Fig. 1b). In all cases
mutation e1369delG associated with the haplotype T A T G
at the four SNPs (P = 0.001) and mutation R311Q with
SNP haplotype G A G C (P = 0.00006).
Intercostal muscle biopsy
Histological and electrophysiological characteristics of
endplates from patients 4–7 are given in supplementary
material. In patients 5 and 6 there was a reduction in the
sensitivity of the endplates towards ACh and a decrease of
the number of secondary synaptic clefts. However, in
patients 4 and 7 the sensitivity of the endplates towards
ACh was almost normal despite the clinical weakness,
suggesting that in these patients the level of expression of
the AChR c subunit is sufficient to effectively compensates
for loss of the e.
Discussion
To date, the Oxford Myasthenia Service has identified
mutations that cause congenital myasthenic syndromes in
17 patients of Dutch origin. Four have mutations that cause
slow channel syndrome, four have mutations in the RAPSN
gene, and nine have mutations that underlie an AChR
deficiency syndrome due to mutations within CHRNE.
Mutation e1369delG was present on at least one allele in
seven of the nine e-subunit gene AChR deficiency patients,
and eR311Q in six. At Oxford the e1369delG and eR311Q
Fig. 1 a Restriction endonuclease digests of PCR amplicons of the
AChR e-subunit gene exons 9 and 12 amplified from genomic DNA.
Affected individuals (shaded) in the kinship (patients 1 and 2) carry
two mutant alleles, whereas members carrying one (half-shaded) are
unaffected. b Example of SNP haplotypes within the 30 untranslated
region of CHRNE showing the kinship containing patients 1 and 2,
derived by DNA sequencing of genomic DNA from family members.
Haplotype T A T G is seen to associate with the allele harbouring
e1369delG and haplotype G A G C with the allele harbouring R311Q
Table 2 Analysis of SNPs
clustered in 30 untranslated
region of CHRNE in Dutch
patients with AChR deficiency
syndrome
Patient SNP
rs1053754 rs8834 rs7774 rs9914357 Mutation Mutation
1 T/G A/A T/G G/C 1369delG R311Q
2 T/G A/A T/G G/C 1369delG R311Q
3 T/T A/A T/T G/G 1369delG 1369delG
4 T/G A/G T/T G/G 1369delG 509insA
5 T/G A/A T/G G/C 1369delG R311Q
6 T/G A/A T/G G/C 1369delG R311Q
7 G/G A/A G/G C/C R311Q R311Q
8 T/G A/A T/G G/G 1369delG Y15H
9 G/G A/A G/G G/C R64X R311Q
Heterozygosity 0.471 0.385 0.481 0.455
Frequency T/G 0.62/0.38 A/G 0.74/0.26 T/G 0.60/0.40 G/C 0.65/0.35
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mutations have not been identified in patients with CMS
from other ethnic origins, but e1369delG has been reported
in a patient from Northern Germany [10]. The common
occurrence of e1369delG and eR311Q, and their strict
association with the respective CHRNE SNP haplotypes
(rs1053754-rs8834-rs7774-rs9914357: T A T G and G A G
C) strongly suggests a founder for each of these mutations
originating in North Western Europe, possibly in Holland.
Most CMS with severe endplate AChR deficiency result
from recessive mutations in AChR e-subunit gene, or the
gene encoding rapsyn. The mutations in the e-subunit are
found along the length of the gene, and result in frameshifts
or nonsense codons that truncate the subunit polypeptide
chain, or loss of residues essential for AChR assembly or
function. More than 90 different AChR e-subunit gene
mutations have been described thus far [11, 12] (and D.
Beeson, unpublished data).
Previous functional studies of the e1369delG mutation,
located close to the subunit C-terminus, have shown that it is
not incorporated into cell surface AChR and thus is a null
allele [9, 10]. Studies of eR311Q show that it is incorporated
into surface AChR pentamers although at severely reduced
levels, and in contrast to another mutation identified in
the same site, eR311W [13], does not affect AChR kinetics [9].
It is thought that patients harbouring homozygous or hetero-
allelic e-subunit null mutations show partial phenotypic
rescue through residual expression of the AChR c-subunit
[7, 13]. Interestingly, symptoms in patient 3, homozygous for
e1369delG, were not substantially more severe than in patients
1, 2, 5 and 6 who are heteroallelic for e1369delG and eR311Q.
In many cases of AChR deficiency syndrome the kinship
is found to have ‘private’ mutations and it may be neces-
sary to screen the entire e-subunit gene coding sequence.
However, it is becoming clear that some e-subunit gene
mutations underlying AChR deficiency syndrome have an
increased incidence in particular geographic regions, pre-
sumably arising from original founder mutations. The best
examples of this are the 1293insG mutation arising in the
Magreb population in North Africa, and in the Gypsy
population of South Eastern Europe where e1267delG is
common [14, 15]. Here we highlight two mutations,
eR311Q and e1369delG, that are common in AChR defi-
ciency syndrome patients of Dutch origin. Knowledge of
the ethnic or geographic origin within Europe of AChR
deficiency patients can help in targeting genetic screening,
and our results suggest that for many patients of Dutch
origin, screening first for eR311Q and e1369delG may
provide a rapid genetic diagnosis.
Acknowledgments We gratefully acknowledge support of the
Prinses Beatrix Fonds (grant no MAR02-0204) to P. C.M. and support
from the MRC and Myasthenia Gravis Association/Muscular Dys-
trophy Campaign to D.B.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Engel AG, Ohno K, Sine SM (1994) Congenital myasthenic
syndromes. In: Engel AG (ed) Myasthenia gravis and myasthenic
disorders. Oxford University Press, New York
2. Beeson D, Newland C, Croxen R, Buckel A, Li FY, Larsson C
et al (1998) Congenital myasthenic syndromes. Studies of the
AChR and other candidate genes. Ann N Y Acad Sci 841:181–
183. doi:10.1111/j.1749-6632.1998.tb10924.x
3. Vincent A, Beeson D, Lang B (2000) Molecular targets for
autoimmune and genetic disorders of neuromuscular transmission.
Eur J Biochem 267(23):6717–6728. doi:10.1046/j.1432-1033.
2000.01785.x
4. Beeson D, Palace J, Vincent A (1997) Congenital myasthenic
syndromes. Curr Opin Neurol 10(5):402–407. doi:10.1097/
00019052-199710000-00008
5. Engel AG, Ohno K, Sine SM (1999) Congenital myasthenic
syndromes: recent advances. Arch Neurol 56(2):163–167. doi:
10.1001/archneur.56.2.163
6. Engel AG, Ohno K, Sine SM (2003) Congenital myasthenic
syndromes: progress over the past decade. Muscle Nerve 27(1):4–
25. doi:10.1002/mus.10269
7. Croxen R, Young C, Slater C, Haslam S, Brydson M, Vincent A
et al (2001) End-plate gamma- and epsilon-subunit mRNA levels
in AChR deficiency syndrome due to epsilon-subunit null muta-
tions. Brain 124(Pt 7):1362–1372. doi:10.1093/brain/124.7.1362
8. Oosterhuis HJGH (1997) Myasthenia gravis. Eight hundred
patients with MG. Groningen Neurological Press, Groningen
9. Ealing J, Webster R, Brownlow S, Abdelgany A, Oosterhuis H,
Muntoni F et al (2002) Mutations in congenital myasthenic
syndromes reveal an epsilon subunit C-terminal cysteine, C470,
crucial for maturation and surface expression of adult AChR.
Hum Mol Genet 11(24):3087–3096. doi:10.1093/hmg/11.24.3087
10. Abicht A, Stucka R, Song IH, Karcagi V, Kugler K, Baumgarten-
Walczak A et al (2000) Genetic analysis of the entire AChR
e-subunit gene in 52 congenital myasthenic families. Acta
Myologica 19:23–28
11. Beeson D, Hantai D, Lochmuller H, Engel AG (2005) 126th
International Workshop: congenital myasthenic syndromes, 24–
26 September 2004, Naarden, the Netherlands. Neuromuscul
Disord 15(7):498–512. doi:10.1016/j.nmd.2005.05.001
12. Engel AG, Sine SM (2005) Current understanding of congenital
myasthenic syndromes. Curr Opin Pharmacol 5(3):308–321. doi:
10.1016/j.coph.2004.12.007
13. Ohno K, Quiram PA, Milone M, Wang HL, Harper MC, Pruitt JN
2nd et al (1997) Congenital myasthenic syndromes due to het-
eroallelic nonsense/missense mutations in the acetylcholine
receptor epsilon subunit gene: identification and functional
characterization of six new mutations. Hum Mol Genet 6(5):753–
766. doi:10.1093/hmg/6.5.753
14. Richard P, Gaudon K, Haddad H, Ammar AB, Genin E, Bauche S
et al (2008) The CHRNE 1293insG founder mutation is a fre-
quent cause of congenital myasthenia in North Africa. Neurology
71(24):1967–1972. doi:10.1212/01.wnl.0000336921.51639.0b
15. Abicht A, Stucka R, Karcagi V, Herczegfalvi A, Horvath R,
Mortier W et al (1999) A common mutation (epsilon1267delG) in
congenital myasthenic patients of Gypsy ethnic origin. Neurology
53(7):1564–1569
J Neurol (2009) 256:1719–1723 1723
123
